Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2020 Oct 12;130(11):6187. doi: 10.1172/JCI144618

Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2

Jia Wang, Peng Cheng, Marat S Pavlyukov, Hai Yu, Zhuo Zhang, Sung-Hak Kim, Mutsuko Minata, Ahmed Mohyeldin, Wanfu Xie, Dongquan Chen, Violaine Goidts, Brendan Frett, Wenhao Hu, Hongyu Li, Yong Jae Shin, Yeri Lee, Do-Hyun Nam, Harley I Kornblum, Maode Wang, Ichiro Nakano
PMCID: PMC7598038  PMID: 33044225

Original citation: J Clin Invest. 2017;127(8):3075–3089. https://doi.org/10.1172/JCI89092

Citation for this retraction: J Clin Invest. 2020;130(11):6187. https://doi.org/10.1172/JCI144618

At the request of the corresponding author, the JCI is retracting this article. Several concerns were raised regarding the Western blot data in Figures 1J, 2A, 3A, and 4D and Supplemental Figures 3A, 4C, and 6A. After an extensive internal review, it became apparent that errors were introduced during the preparation of the revised figures. Due to loss of confidence in the published figures, the corresponding author requested retraction. No issues have been raised with regard to any of the other data in the paper.

Version 1. 10/12/2020

Electronic publication

Version 2. 11/02/2020

Print issue publication

Footnotes


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES